Citadel Advisors
RUBY

Citadel Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Citadel Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-132,322
Closed -$22.8K – 16079
2022
Q4 		$22.8K Sell
132,322
-9,458
-7% -$2.58K ﹤0.01% 13040
2022
Q3 		$62K Sell
141,780
-211,030
-60% -$158K ﹤0.01% 11484
2022
Q2 		$300K Buy
352,810
+64,281
+22% +$108K ﹤0.01% 9806
2022
Q1 		$1.59M Buy
288,529
+227,686
+374% +$1.45M ﹤0.01% 6604
2021
Q4 		$589K Buy
60,843
+41,794
+219% +$580K ﹤0.01% 9284
2021
Q3 		$341K Buy
+19,049
New +$414K ﹤0.01% 10773
2021
Q1 		– Sell
-70,955
Closed -$539K – 13900
2020
Q4 		$539K Sell
70,955
-12,334
-15% -$73.3K ﹤0.01% 8001
2020
Q3 		$417K Buy
83,289
+49,587
+147% +$263K ﹤0.01% 7595
2020
Q2 		$202K Sell
33,702
-106,701
-76% -$630K ﹤0.01% 8515
2020
Q1 		$625K Sell
140,403
-52,462
-27% -$390K ﹤0.01% 6123
2019
Q4 		$1.83M Sell
192,865
-73,596
-28% -$712K ﹤0.01% 4551
2019
Q3 		$2.09M Buy
266,461
+51,498
+24% +$600K ﹤0.01% 4423
2019
Q2 		$3.38M Buy
+214,963
New +$3.47M ﹤0.01% 3674

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

Citadel Advisors's RUBY Position: Q1 2023 in Review

Citadel Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 132,322 shares — an estimated $22.8K sold.

Citadel Advisors first reported a position in RUBY in Q2 2019 and held it in 13 quarters. The position peaked at $3.38M in Q2 2019. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • Citadel Advisors reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 132,322 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $22.8K.
  • Citadel Advisors first reported a position in Rubius Therapeutics, Inc in Q2 2019 and held it in 13 quarters.
  • Citadel Advisors's Rubius Therapeutics, Inc position peaked at $3.38M in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.